TABLE 6.
Baseline characteristics of the CPRD‐HES BMI groups
| BMI group | Normal 18.5–24.9 kg/m2 | 25.0–29.9 kg/m2 | 30–34.9 kg/m2 | 35–39.9 kg/m2 | 40–44.9 kg/m2 |
|---|---|---|---|---|---|
| N | 1,099,106 | 1,074,953 | 507,425 | 176,237 | 67,231 |
| Mean age, years (SD) | 48.5 (19.2) | 53.1 (16.9) | 52.1 (15.9) | 49.3 (15.4) | 47.4 (14.6) |
| Mean BMI, kg/m2 (SD) | 22.5 (1.7) | 27.3 (1.4) | 32.1 (1.4) | 37.0 (1.4) | 42.3 (1.5) |
| Mean height, m (SD) | 1.68 (0.09) | 1.69 (0.10) | 1.68 (0.10) | 1.66 (0.10) | 1.65 (0.10) |
| Smoking, % ever smoked | 49.3 | 50.2 | 50.6 | 48.8 | 47.3 |
| Sex, % women | 64.6 | 49.7 | 53.1 | 62.9 | 70.9 |
| Individuals on antihypertension medication, % | 14.7 | 22.3 | 26.1 | 26.7 | 28.5 |
| Individuals on lipid‐lowering medication, % | 8.3 | 13.9 | 15.7 | 14.6 | 14.9 |
| Mean SBP, mmHg (SD) | 128.2 (71.4) | 135.4 (73.8) | 138.3 (54.2) | 139.4 (56.7) | 140.0 (57.7) |
| Mean total cholesterol, mg/dl (SD) | 203.7 (41.5) | 207.8 (42.0) | 208.0 (42.2) | 206.2 (41.7) | 201.2 (40.9) |
| Mean HDL, mg/dl (SD) | 61.0 (18.1) | 53.9 (16.5) | 50.4 (15.3) | 48.8 (14.4) | 47.5 (14.2) |
| Mean HbA1c, % (SD) | 7.5 (1.6) | 7.6 (1.5) | 7.7 (1.5) | 7.8 (1.5) | 7.8 (1.6) |
| Mean triglycerides, mg/dl (SD) | 118.9 (69.0) | 152.2 (87.9) | 175.0 (98.1) | 180.1 (99.4) | 177.0 (94.6) |
| Individuals with triglyceride levels ≥150 mg/dl, % | 22.4 | 40.0 | 51.7 | 54.3 | 53.8 |
| Individuals without pre‐T2D or T2D a , b , % | 95.3 | 90.2 | 85.5 | 82.5 | 78.8 |
| Individuals with pre‐T2D with laboratory values, % | 2.0 | 4.1 | 5.9 | 6.9 | 6.7 |
| Individuals with T2D, % | 2.7 | 5.7 | 8.6 | 10.6 | 14.5 |
| T2D duration, years (SD) | 5.9 (6.9) | 5.0 (6.1) | 4.5 (5.6) | 4.3 (5.4) | 4.1 (5.1) |
Abbreviations: BMI, body mass index; CPRD‐HES, Clinical Practice Research Datalink‐Hospital Episode Statistics; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; SBP, systolic blood pressure; SD, standard deviation; T2D, type 2 diabetes.
a
Calculated as 100% minus the proportions of individuals with pre‐T2D or T2D.
b
In scenario analyses that adjusted prediabetes prevalence to real‐world values, distribution at baseline was modified to 25.9% prediabetes, 2.7% T2D and 71.4% nonprediabetes and non‐T2D.